Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
42,101,464
-
Share change
-
-73,468,751
-
Total reported value
-
$5,465,824
-
Put/Call ratio
-
104%
-
Price per share
-
$0.13
-
Number of holders
-
54
-
Value change
-
-$18,296,164
-
Number of buys
-
20
-
Number of sells
-
35
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q3 2025
As of 30 Sep 2025,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
54 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
42,101,464 shares.
The largest 10 holders included
Long Focus Capital Management, LLC, UBS Group AG, RENAISSANCE TECHNOLOGIES LLC, MORGAN STANLEY, JANE STREET GROUP, LLC, ACADIAN ASSET MANAGEMENT LLC, BANK OF AMERICA CORP /DE/, Empirical Finance, LLC, B. Riley Wealth Advisors, Inc., and Rathbones Group PLC.
This page lists
54
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.